Nuo Therapeutics, Inc. (AURX)
| Market Cap | 62.93M-46.7% |
| Revenue (ttm) | n/a+166.6% |
| Net Income | n/a+18.5% |
| EPS | n/a+21.3% |
| Shares Out | 48.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,356 |
| Open | 1.30 |
| Previous Close | 1.30 |
| Day's Range | 1.30 - 1.30 |
| 52-Week Range | 0.77 - 2.92 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 3.00(+130.77%) |
| Earnings Date | n/a |
Nuo Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About AURX
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AURX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AURX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AURX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AURX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AURX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AURX from public contracts
Source: USAspending.gov
AURX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AURX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score